journal article·2024-11-21Open access

Is There an Ideal Concentration of Ozonized Oil for the Prevention and Modulation of Zoledronate-Induced Mandibular Osteonecrosis? A Study on Senescent Rats

Mirela Caroline Silva, Izabela Fornazari Delamura, Maria Eloise de Sá Simon, Stefany Barbosa, David Tawei Ting, Karen Bechara, Jamil Awad Shibli, Carlos Fernando Mourão, Ana Paula Farnezi Bassi, Edilson Ervolino, Leonardo Perez Faverani

Journal of Functional Biomaterials· Volume 15· Issue 12

Abstract

This study aimed to identify whether there is an ideal concentration for applying ozonized oil (OZ) in the post-exodontic alveoli of senescent rats treated with zoledronate (ZOL). Thirty-five female rats, aged 18 months, were divided into five groups: ZOL; ZOL+OZ500; ZOL+OZ600; ZOL+OZ700; and SAL. The groups treated with ZOL, and other concentrations of OZ received applications at a dose of 100 μg/kg, while the SAL group received saline. After three weeks of ZOL application, the animals underwent extraction of the lower first molar. Subsequently, local therapies were initiated: group ZOL+OZ500 at 500 mEq/kg; ZOL+Z600 at 600 mEq/kg; and ZOL+OZ700 at 700 mEq/kg at baseline, and on days 2 and 4 post-operation. Euthanasia was performed on day 28. The microtomographic parameter of bone volume and histometric data on the area of neoformed bone (NFBT) showed the highest values for the ZOL+OZ600 group (p < 0.05). All OZ groups had smaller areas of non-vital bone than the ZOL group (p < 0.05). The clinical appearance of the operated region showed the alveoli covered with soft tissue, particularly in the OZ groups. All the tested concentrations of OZ were able to prevent and modulate MRONJ. As it presents a greater amount of NFBT, the concentration of 600 mEq/kg seems to be ideal.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone health and treatments · Osteomyelitis and Bone Disorders Research · Medical and Biological Ozone Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Diagnosis and Surgery, Araçatuba School of Dentistry, Sao Paulo State University (UNESP), Araçatuba 16015-050, Sao Paulo, Brazil

Dental Research Division, Department of Periodontology and Oral Implantology, Federal Fluminense Univesity, Niteroi 21941-617, Rio de Janeiro, Brazil

Dental Research Division, Department of Periodontology and Oral Implantology, University of Guarulhos (UnG), Guarulhos 07115-230, Sao Paulo, Brazil

Department of Basic and Clinical Translational Sciences, Tufts University School of Dental Medicine, Boston, MA 02111, USA

Department of Basic Sciences, Araçatuba School of Dentistry, Sao Paulo State University (UNESP), Araçatuba 16015-050, Sao Paulo, Brazil

Department of Oral Diagnosis, Division of Oral and Maxillofacial Surgery, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba 13414-903, Sao Paulo, Brazil

OMFS, School of Dentistry, São Paulo State University, Araçatuba 16015-050, Sao Paulo, Brazil

References (36)

Show source-provided references
1. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update10.1016/j.joms.2014.04.031 ↗
2. Jamalpour, M.R., Shahabi, S., Baghestani, M., Shokri, A., Jamshidi, S., and Khazaei, S. (2022). Complementarity of surgical therapy, photobiomodulation, A-PRF and L-PRF for management of medication-related osteonecrosis of the jaw (MRONJ): An animal study. BMC Oral Health, 22.10.1186/s12903-022-02275-2 ↗
3. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment10.1016/j.joms.2007.08.003 ↗
4. Risk factors for medication-related osteonecrosis of the jaws: A systematic review10.1111/odi.12708 ↗
5. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases10.1016/j.joms.2004.02.004 ↗
6. Impact of bisphosphonate therapy on dental implant outcomes: An overview of systematic review evidence10.1016/j.ijom.2018.09.006 ↗
7. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review10.1016/j.jcms.2017.05.028 ↗
8. Bisphosphonate treatment and dental implants: A systematic review
9. Antimicrobial photodynamic therapy improves the alveolar repair process and prevents the occurrence of osteonecrosis of the jaws after tooth extraction in senile rats treated with zoledronate10.1016/j.bone.2018.10.014 ↗
10. Osteochemonecrosis of the jaws due to bisphosphonate treatments: Update
11. Pathophysiology of osteonecrosis of the jaws10.1016/j.coms.2015.06.001 ↗
12. Preexisting periapical inflammatory condition exacerbates tooth extraction–induced bisphosphonate-related osteonecrosis of the jaw lesions in mice10.1016/j.joen.2016.07.020 ↗
13. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw10.1902/jop.2013.130017 ↗
14. Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): A retrospective single-center study10.1016/j.oooo.2020.10.018 ↗
15. The effects of allograft combined with ozone therapy on regeneration of calvarial defects in rats10.7126/cumudj.298891 ↗
16. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw10.1016/j.oooo.2019.08.004 ↗
17. Effectiveness of laser-assisted treatments for medication-related osteonecrosis of the jaw: A systematic review10.1016/j.bjoms.2019.12.001 ↗
18. Scientific and medical aspects of ozone therapy. State of the art10.1016/j.arcmed.2005.08.006 ↗
19. Mauceri, R., Panzarella, V., Pizzo, G., Oteri, G., Cervino, G., Mazzola, G., Di Fede, O., and Campisi, G. (2020). Platelet-Rich Plasma (PRP) in Dental Extraction of Patients at Risk of Bisphosphonate-Related Osteonecrosis of the Jaws: A Two-Year Longitudinal Study. Appl. Sci., 10.10.3390/app10134487 ↗
20. Ozonated oil effect for prevention of medication-related osteonecrosis of the jaw (MRONJ) in rats undergoing zoledronic acid therapy10.1007/s00784-021-03951-3 ↗
21. Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I–II study10.1016/j.oraloncology.2011.01.002 ↗
22. Xiao, W., Tang, H., Wu, M., Liao, Y., Li, K., Li, L., and Xu, X. (2017). Ozone oil promotes wound healing by increasing the migration of fibroblasts via PI3K/Akt/mTOR signaling pathway. Biosci. Rep., 37.10.1042/BSR20170658 ↗
23. Histomorphometric evaluation of the effect of systemic and topical ozone on alveolar bone healing following tooth extraction in rats10.1016/j.ijom.2013.12.007 ↗
24. Histomorphometric and microtomographic evaluation of the effects of hyperbaric oxygen and systemic ozone, used alone and in combination, on calvarial defect healing in rats10.1016/j.joms.2015.02.018 ↗
25. Aplicações clínicas do ozônio na odontologia: Revisão de literatura
26. Ozonated Oils and Cutaneous Wound Healing10.2174/1381612825666190702100504 ↗
27. Ozone improved bone dynamic of female rats using zoledronate10.1089/ten.tec.2023.0159 ↗
28. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
29. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton10.1016/j.bone.2020.115493 ↗
30. Genotoxicity and cytotoxicity in multiple organs induced by titanium miniplates in Wistar rats10.1002/jbm.a.31876 ↗
31. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaw–2022 Update10.1016/j.joms.2022.02.008 ↗
32. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis?10.1016/j.joms.2006.02.011 ↗
33. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion10.1016/j.joms.2011.02.049 ↗
34. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus10.1002/jbmr.2405 ↗
35. Ozone and ozonated oils in skin diseases: A review10.1155/2010/610418 ↗
36. Lipid mediators in skin inflammation: Updates and current views10.1155/2010/398926 ↗